| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tomiki Sumiyosh. Possible dose-side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia. Expert review of clinical pharmacology. vol 1. issue 6. 2014-01-14. PMID:24410608. |
on the other hand, treatment with some atypical agents, such as risperidone, may deteriorate working memory in some people with early-stage schizophrenia. |
2014-01-14 |
2023-08-12 |
Not clear |
| Sa Jacob, Mi Mohamed Ibrahim, F Mohamme. Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia. Mental health in family medicine. vol 10. issue 1. 2014-01-01. PMID:24381653. |
polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in malaysia. |
2014-01-01 |
2023-08-12 |
Not clear |
| Sa Jacob, Mi Mohamed Ibrahim, F Mohamme. Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia. Mental health in family medicine. vol 10. issue 1. 2014-01-01. PMID:24381653. |
the present study was conducted primarily to determine the occurrence of polypharmacy in patients with schizophrenia on risperidone. |
2014-01-01 |
2023-08-12 |
Not clear |
| Yutaro Suzuki, Takuro Sugai, Naoki Fukui, Junzo Watanabe, Shin Ono, Nobuto Tsuneyama, Mami Saito, Toshiyuki Somey. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Human psychopharmacology. vol 28. issue 3. 2013-12-18. PMID:23553637. |
we examined sex differences in the effect of olanzapine (olz), risperidone (ris), aripiprazole (arp), or quetiapine (qtp) on mean corrected qt (qtc) intervals among 222 patients with schizophrenia. |
2013-12-18 |
2023-08-12 |
Not clear |
| Vladan Novakovic, Tymaz Adel, Eric Peselow, Jean-Pierre Lindenmaye. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clinical neuropharmacology. vol 36. issue 2. 2013-12-13. PMID:23503549. |
five long-acting injectable (lai) antipsychotics are currently available in the united states for the treatment of schizophrenia: fluphenazine decanoate, haloperidol decanoate, risperidone microspheres, paliperidone palmitate, and olanzapine pamoate. |
2013-12-13 |
2023-08-12 |
Not clear |
| b' Xue Li, Xue-qin Song, Jin-song Gao, Li-juan Pang, You-hui Li, Yi-hui Hao, Lu-xian L\\xc3\\xb. [Proteomic analysis of novel serum markers in first-episode schizophrenics before versus after treatment of risperidone]. Zhonghua yi xue za zhi. vol 92. issue 45. 2013-11-25. PMID:23328465.' |
to explore the changes in serum protein levels of schizophrenics before and after treatment of risperidone and identify the potential markers of diagnosis, treatment and drug side effects of schizophrenia. |
2013-11-25 |
2023-08-12 |
Not clear |
| M Bennie, I Bishop, B Godman, C Barbui, E Raschi, S Campbell, J Miranda, L L Gustafsso. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. International journal of clinical practice. vol 67. issue 2. 2013-11-19. PMID:23305478. |
generic oral risperidone recently became available in scotland; however, schizophrenia is a complex disease with advice from respected authorities suggesting that treatment should be individualised. |
2013-11-19 |
2023-08-12 |
Not clear |
| Farzin Rezaei, Maryam Mohammad-Karimi, Sahar Seddighi, Amirhossein Modabbernia, Mandana Ashrafi, Bahman Salehi, Siran Hammidi, Hamid Motasami, Reza Hajiaghaee, Mina Tabrizi, Shahin Akhondzade. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology. vol 33. issue 3. 2013-11-07. PMID:23609382. |
memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. |
2013-11-07 |
2023-08-12 |
Not clear |
| Farzin Rezaei, Maryam Mohammad-Karimi, Sahar Seddighi, Amirhossein Modabbernia, Mandana Ashrafi, Bahman Salehi, Siran Hammidi, Hamid Motasami, Reza Hajiaghaee, Mina Tabrizi, Shahin Akhondzade. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology. vol 33. issue 3. 2013-11-07. PMID:23609382. |
in a double-blind placebo-controlled clinical trial, 40 patients with schizophrenia (diagnostic and statistical manual of mental disorders, fourth edition) who were stabilized on risperidone for a minimum of 8 weeks were randomized to either memantine (20 mg) or placebo in addition to risperidone, 6 mg/d, for eight weeks. |
2013-11-07 |
2023-08-12 |
Not clear |
| Yueren Zhao, Taro Kishi, Nakao Iwata, Manabu Iked. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia. Neuropsychiatric disease and treatment. vol 9. 2013-11-06. PMID:24194642. |
combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia. |
2013-11-06 |
2023-08-12 |
Not clear |
| Yueren Zhao, Taro Kishi, Nakao Iwata, Manabu Iked. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia. Neuropsychiatric disease and treatment. vol 9. 2013-11-06. PMID:24194642. |
the aim of this study was to examine whether addition of compass to risperidone lai was more effective in preventing relapse in schizophrenia patients than risperidone lai alone, with the latter group consisting of patients enrolled in a phase iii trial of risperidone lai in japan. |
2013-11-06 |
2023-08-12 |
Not clear |
| David N Osser, Mohsen Jalali Roudsari, Theo Manschrec. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harvard review of psychiatry. vol 21. issue 1. 2013-10-29. PMID:23656760. |
the first-line treatment recommendation for new-onset schizophrenia is with amisulpride, aripiprazole, risperidone, or ziprasidone for four to six weeks. |
2013-10-29 |
2023-08-12 |
Not clear |
| Enrico Smeraldi, Roberto Cavallaro, Vera Folnegović-Šmalc, Leszek Bidzan, Mehmet Emin Ceylan, Andreas Schreine. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Therapeutic advances in psychopharmacology. vol 3. issue 4. 2013-10-29. PMID:24167692. |
long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre). |
2013-10-29 |
2023-08-12 |
Not clear |
| Enrico Smeraldi, Roberto Cavallaro, Vera Folnegović-Šmalc, Leszek Bidzan, Mehmet Emin Ceylan, Andreas Schreine. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Therapeutic advances in psychopharmacology. vol 3. issue 4. 2013-10-29. PMID:24167692. |
the objective of this study was to report the long-term remission results from the constatre relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (rlai) or oral quetiapine, dosed according to package-insert recommendations. |
2013-10-29 |
2023-08-12 |
Not clear |
| M Horiguchi, H Y Meltze. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism. Behavioural brain research. vol 247. 2013-10-21. PMID:23538066. |
these results suggest that blonansein and risperidone, atypical apds which lack a direct action on 5-ht1a receptors require 5-ht1a receptor stimulation to reverse the subchronic pcp-induced nor deficit and provide a support for clinical trial of blonanserin in combination with tandospirone to ameliorate cognitive impairment in schizophrenia and to have fewer side effects. |
2013-10-21 |
2023-08-12 |
rat |
| Mark E Bushong, Paul A Nakonezny, Matthew J Byerl. Subjective quality of life and sexual dysfunction in outpatients with schizophrenia or schizoaffective disorder. Journal of sex & marital therapy. vol 39. issue 4. 2013-09-30. PMID:23421823. |
the authors evaluated a sample of 238 adult outpatients with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine, olanzapine, or risperidone at study entry with a 1-time rating of the arizona sexual experience scale and the general life satisfaction scale item of the quality of life index. |
2013-09-30 |
2023-08-12 |
Not clear |
| Anirban Ray, Bhaskar Mukherje. A case of resistant schizophrenia responding at a higher than recommended dose of risperidone without significant side effects. Indian journal of pharmacology. vol 45. issue 1. 2013-09-26. PMID:23543286. |
a case of resistant schizophrenia responding at a higher than recommended dose of risperidone without significant side effects. |
2013-09-26 |
2023-08-12 |
Not clear |
| Tomomi Tenjin, Seiya Miyamot. [Blonanserin in the treatment of schizophrenia]. Nihon rinsho. Japanese journal of clinical medicine. vol 71. issue 4. 2013-09-25. PMID:23678596. |
several short-term double-blind trials demonstrated that blonanserin was well tolerated and had equal efficacy to haloperidol and risperidone in terms of positive symptoms and depressive symptoms in patients with chronic schizophrenia. |
2013-09-25 |
2023-08-12 |
Not clear |
| Xiaofeng Hu, Jishui Zhang, Chao Jin, Weifeng Mi, Fang Wang, Wenbin Ma, Cuicui Ma, Yongfeng Yang, Wenqiang Li, Hongxing Zhang, Bo Du, Keqing Li, Chenxing Liu, Lifang Wang, Tianlan Lu, Hongyan Zhang, Luxian Lv, Dai Zhang, Weihua Yu. Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population. Progress in neuro-psychopharmacology & biological psychiatry. vol 43. 2013-09-19. PMID:23306218. |
our findings suggested that nrxn3 might represent a major susceptibility gene for schizophrenia and have a role in bodyweight gain related to therapy of risperidone in chinese han population. |
2013-09-19 |
2023-08-12 |
human |
| Bong Ju Lee, Seung Ju Lee, Min Kyung Kim, Jung Goo Lee, Sung Woo Park, Gyung Mee Kim, Young Hoon Ki. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 11. issue 2. 2013-09-11. PMID:24023549. |
effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. |
2013-09-11 |
2023-08-12 |
Not clear |